BTK and atrial fibrillation: A more selective, noncovalent, reversible BTK inhibitor pirtobrutinib was also developed for patients with B-cell malignancies refractory to first and second-generation BTK inhibitors, and AF rates remained low at 3.8% in a recent phase 1–2 clinical trial [39].